{"id":"W2922526627","doi":"10.1016/j.bpg.2019.03.002","title":"Pharmacology, efficacy and safety of JAK inhibitors in Crohn’s disease","year":2019,"lang":"en","type":"review","venue":"Best Practice & Research Clinical Gastroenterology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":33,"is_retracted":false,"has_abstract":false,"ca_institutions":"Western University; Robarts Clinical Trials; University of Calgary","funders":"Canadian Institutes of Health Research; Canadian Association of Gastroenterology; American Gastroenterological Association","keywords":"Medicine; Tofacitinib; Clinical endpoint; Clinical trial; Internal medicine; Placebo; Phases of clinical research; Crohn's disease; Janus kinase; Pharmacology; Oncology; Disease; Cytokine; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.007071136,0.0005090873,0.001667687,0.0004087407,0.00008254197,0.00003654346,0.0008380674,0.0008492542,0.0000723214],"category_scores_gemma":[0.01025478,0.00047297,0.0005446224,0.0002229892,0.001536173,0.00002739878,0.00164546,0.002289875,0.0001427222],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008260347,"about_ca_system_score_gemma":0.001400657,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002259681,"about_ca_topic_score_gemma":0.00005604388,"domain_scores_codex":[0.9853538,0.009541951,0.002123678,0.00140679,0.0005016641,0.001072096],"domain_scores_gemma":[0.9946516,0.00223914,0.0008758617,0.001041698,0.0004719387,0.0007197206],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.07748199,0.01328883,0.05593412,0.026186,0.002552747,0.008224811,0.00005084748,0.00002276313,0.0000785165,0.0001176593,0.02158077,0.7944809],"study_design_scores_gemma":[0.00377014,0.002064152,0.01372527,0.001713361,0.0008903473,0.00006965072,0.00003483488,0.000006108327,7.990187e-7,0.00000577603,0.9774674,0.0002521965],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.05441344,0.9401337,0.0000104383,0.0004489146,0.0008801573,0.003469629,0.0002351015,0.00001210272,0.0003965497],"genre_scores_gemma":[0.003085478,0.9948326,0.0001416762,0.0003369125,0.000780534,0.0002373542,0.0002515721,0.00009252368,0.0002414],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9558866,"threshold_uncertainty_score":0.9997722,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1082905367393629,"score_gpt":0.4957671911948989,"score_spread":0.387476654455536,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}